2015 NEJM study of 4g acetaminophen vs PBO in 700 critically ill ICU patients with fever ≥38°C, showed Tylenol vs PBO had no differences in mortality, ICU stay or LFTs. Tylenol had small but signif reduction in Temp (38.4±1.0°C vs. 38.6±0.8°C; P<0.001) https://t.co/qnHgFRp20M https://t.co/2E4ZEsIFUV

French study from 362 septic arthritis pts over 2 yrs., mean age was 64yrs, w/ high Charlson comorbidity index 3.5. Most common was Knee (39%), Staphylococcus (51%), Abx used 47d, surgery in 48%; 28% serious complications & 9.2% died https://t.co/P2nxnhDnut https://t.co/KoZoe1yib4

JAMA patient (resource) handout on Lumbar Spinal Stenosis! https://t.co/MR7aIrP0Pq https://t.co/Q6rvddbnvT

162 #AOSD or #sJIA criteria+ pts underwent genetic testing - 31% (51/162) had a genetic variant for periodic fever Dx. 4 SJIA pts were confirmed to have FMF or TRAPS. Genetic testing may be smart, esp w/ atypical presentations https://t.co/hwZFgOL4j4 https://t.co/6y8r1Dyv1A

Abatacept Most Effective Early and in Seropositive RA A 2 year study evaluated the efficacy and safey (drug retention) of subcutaneous ABA in active RA and showed superior responses when ABA was given to biologic-naive and seropositive RA patients. https://t.co/WdZ3YCeGXg https://t.co/4ZjFFrVmSJ

11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/NqGOislcIJ https://t.co/tqk3jF3Lxg

Cochrane metanalysis of sleep meds - 170 trials (36 interventions, 47950 pts). Doxepin, seltorexant, zaleplon well tolerated, but efficacy data is scarce. Benzodiazepines, eszopiclone, zolpidem, were more efficacious, but zolpidem more dropouts due to AEs https://t.co/8mPYmfTAaR https://t.co/DqUFcgq9AR

Leflunomide versus azathioprine in lupus nephritis? Study of 215 bx proven LN given either LEF or AZA - Renal flares were equal (15.7% v 17.8%), as was time to flare (16 mo vs AZA 14 mo); 24-hr proteinuria, creatinine, C3 and C4 improved similarly. https://t.co/FEKwwyoJhZ https://t.co/zUyHXGjpOD

Watch: Remote Monitoring Technologies in the Management of RA Dr. Antoni Chan interviews Dr. Johannes Knitza at EULAR 2022 https://t.co/SU9SUScHiS https://t.co/YoxQPZH5eQ

Seminal Articles on Stills disease Tues Nite Rheum Journal Club tommorrow Discussants: Drs. Bella Mehta, Michael Weisman & Jack Cush 7pm EDT (4pmPDT) - The 1st articles on AOSD from Bywaters & Bujak https://t.co/yRgHlmZHhi https://t.co/ooexkgM6ga Register: https://t.co/kstge3gAcl https://t.co/XjQJi4FRmt

Study of 50 #AOSD pts refractory to steroids (n=11), DMARDs (34) & biologics (n 30): given canakinumab 150–300 mg q 4wk (47) or q8wk(3). W/ 27 mos F/U: 78% complete resp w/in 3 mos (20% partial). Steroid sparing in 1/2, Low WBC 6%, 4%SIE https://t.co/QMCLictdrL https://t.co/5hkUOBFDG0